Novel Communications in Diabetes

Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes

  1. Matthew J. Crowley1,2⇑,
  2. John W. Williams Jr.1,3,
  3. Andrzej S. Kosinski4,
  4. David A. D’Alessio2 and
  5. John B. Buse5
  1. 1Durham Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC
  2. 2Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke University School of Medicine, Durham, NC
  3. 3Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC
  4. 4Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC
  5. 5Division of Endocrinology & Metabolism, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC
  1. Corresponding author: Matthew J. Crowley, matthew.crowley{at}dm.duke.edu.
Diabetes Care 2017 Dec; 40(12): 1787-1789. https://doi.org/10.2337/dc17-1528

Article Figures & Tables

Figures

  • Figure 1
    Figure 1

    Forest plot depicting the effect of DPP-4i on primary composite study outcomes, stratified by metformin user/nonuser subgroups (P = 0.036 for difference in DPP-4i effect between prevalent metformin users and baseline nonusers). N = number of patients.

Back to top
View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Add to Selected Citations

Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes
Matthew J. Crowley, John W. Williams, Andrzej S. Kosinski, David A. D’Alessio, John B. Buse
Diabetes Care Dec 2017, 40 (12) 1787-1789; DOI: 10.2337/dc17-1528
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section